Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.

Front Oncol · 2020 · PMC7930562 · PMID 33680957

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Adjuvant therapy in non-ulcerated melanomas with macro-metastases was associated with the smallest RFS benefit and did not reach statistical significance (HR 0.73; 95%CI= 0.50–1.05) ( eFigure 4, supplement ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.